Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies

被引:0
|
作者
Kaiyue Wang
Lu Shen
Wei Tian
Suzhan Zhang
机构
[1] Zhejiang University,Department of Breast Surgery, the Second Affiliated Hospital, School of Medicine
[2] Zhejiang University,Cancer Institute (The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Department of Surgical Oncology, the Second Affiliated Hospital, School of Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids. This study enrolled 160 premenopausal patients with stage I–III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment and past medical history. The changes in blood lipids in patients receiving different types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after initiating endocrine therapy. Generalized linear mixed model was used in our analyses. Our data revealed that low-density lipoprotein cholesterol (LDL-C) levels in patients with tamoxifen (TAM) were significantly lower in the 6th, 12th, and 24th months than that in the 3rd month, while high-density lipoprotein cholesterol (HDL-C) levels in the 6th, 12th, and 24th months were significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C levels were significantly higher in the 24th month than in the 3rd month, total cholesterol (TC) levels were significantly higher in the 24th month than in the 6th month. The lipid profiles of OFS plus aromatase inhibitor (AI) group did not show significant differences at any time point but were significantly higher than those of the other two groups especially in LDL and TC. TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values was observed between TAM and TAM plus OFS groups at various time points. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size.
引用
收藏
相关论文
共 50 条
  • [21] Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Bao, Ting
    Davidson, Nancy E.
    [J]. BREAST CANCER RESEARCH, 2007, 9 (06)
  • [22] Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Dellapasqua, S
    Colleoni, M
    Gelber, RD
    Goldhirsch, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) : 1736 - 1750
  • [23] Comparison of dyslipidemia incidence in Chinese early-stage breast cancer patients following different endocrine therapies: A population-based cohort study
    Wang, Junren
    Yin, Jin
    Qiu, Jiajun
    Jiang, Jingwen
    Hu, Yao
    Zhu, Kunrui
    Zheng, Hong
    Luo, Ting
    Zhong, Xiaorong
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [24] Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer
    Tian, Sibo
    Paster, Lina F.
    Kim, Sinae
    Kirstein, Laurie
    Haffty, Bruce G.
    Ferro, Adam
    Amorosa, Judith
    Goyal, Sharad
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (02): : 597 - 604
  • [25] Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer
    Mayo, R. C., III
    [J]. BREAST DISEASES, 2016, 27 (04): : 275 - 275
  • [26] What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
    Higgins M.J.
    Davidson N.E.
    [J]. Current Breast Cancer Reports, 2009, 1 (1) : 42 - 47
  • [27] What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
    Michaela J. Higgins
    Nancy E. Davidson
    [J]. Current Oncology Reports, 2009, 11 : 45 - 50
  • [28] Brachytherapy boost in women with early-stage breast cancer treated with breast conserving therapy
    Glinski, Bogdan
    Zabek, Magdalena
    Mitus, Maria
    [J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2007, 12 (01) : 47 - 51
  • [29] What Is the Current Status of Ovarian Suppression/Ablation in Women With Premenopausal Early-Stage Breast Cancer?
    Higgins, Michaela J.
    Davidson, Nancy E.
    [J]. CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 45 - 50
  • [30] High prevalence of vitamin D deficiency in premenopausal women with early-stage breast cancer.
    Hershman, D. L.
    McMahon, D.
    Irani, D.
    Cucchiara, G.
    Crew, K.
    Raptis, G.
    Shane, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 485S - 485S